CIK 0001999480 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Alto Neuroscience, Inc.
Sign in to watch- Ticker
- ANRO
- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 834210124
- Phone
- 773-255-5012
- Business address
- 650 CASTRO STREET, SUITE 450, MOUNTAIN VIEW, CA, 94041
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $3,567,247
- in 1 filing
Net −$3,567,247. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-03-28 | Smith Nicholas Conrad CHIEF FINANCIAL OFFICER | Purchase | +4,550 | $16.56 | $75K | 26,866 |
| 2024-03-08 | Radhakrishnan Maha Director | Grant or award · Stock Option (right to buy) | +30,574 | 30,574 | ||
| 2024-03-08 | Radhakrishnan Maha Director | Grant or award · Stock Option (right to buy) | +1,590 | $10.21 | $16K | 1,590 |
| 2024-03-01 | Savitz Adam CHIEF MEDICAL OFFICER | Grant or award · Employee Stock Option (Right to Buy) | +73,000 | 73,000 | ||
| 2024-03-01 | Smith Nicholas Conrad CHIEF FINANCIAL OFFICER | Grant or award | +19,153 | 20,716 | ||
| 2024-03-01 | Smith Nicholas Conrad CHIEF FINANCIAL OFFICER | Grant or award · Employee Stock Option (Right to Buy) | +90,000 | 90,000 | ||
| 2024-03-01 | Etkin Amit PRESIDENT AND CEO | Grant or award | +34,711 | 1,240,176 | ||
| 2024-03-01 | Etkin Amit PRESIDENT AND CEO | Grant or award · Employee Stock Option (Right to Buy) | +223,000 | 223,000 | ||
| 2024-02-06 | Apeiron Investment Group Ltd. See Remarks | Conversion | +251,881 | 251,881 | ||
| 2024-02-06 | Apeiron Investment Group Ltd. See Remarks | Conversion | +674,658 | 674,658 | ||
| 2024-02-06 | Apeiron Investment Group Ltd. See Remarks | Conversion · Warrants to Purchase Series A Preferred Stock | −444,561 | 0 | ||
| 2024-02-06 | Apeiron Investment Group Ltd. See Remarks | Conversion · Series A Preferred Stock | −406,072 | 0 | ||
| 2024-02-06 | Apeiron Investment Group Ltd. See Remarks | Conversion · Series A Preferred Stock | −1,063,918 | 0 | ||
| 2024-02-06 | Apeiron Investment Group Ltd. See Remarks | Conversion · Series B Preferred Stock | −416,665 | 0 | ||
| 2024-02-06 | Alpha Wave Global, LP 10% owner | Conversion | +1,962,995 | 1,962,995 | ||
| 2024-02-06 | Alpha Wave Global, LP 10% owner | Conversion | +1,144,762 | 3,107,757 | ||
| 2024-02-06 | Alpha Wave Global, LP 10% owner | Purchase | +600,000 | $16.00 | $9.6M | 3,707,757 |
| 2024-02-06 | Alpha Wave Global, LP 10% owner | Conversion · Series B Convertible Preferred Stock (Series B Preferred) | −1,962,995 | 0 | ||
| 2024-02-06 | Alpha Wave Global, LP 10% owner | Conversion · Series C Convertible Preferred Stock (Series C Preferred) | −1,144,763 | 0 | ||
| 2024-02-06 | York Gwill Director | Conversion | +23,917 | 23,917 |
Page 5 of 7 · 125 trades